HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 28 February 2011

DSU report on azacitidine

Work undertaken by the DSU in support of the ongoing technology appraisal of azacitidine (Vidaza, Celgene) is now available (dated December 2010).  In the latest draft guidance, NICE recommends azacitidine as a treatment option for a sub-group of patients with myelodysplastic syndromes and related conditions.  This decision is based on a revised patient access scheme and the application of the end-of-life guidance.

For further information, contact Paul Tappenden.